Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Observational Study of the Safety of Herceptin Given Subcutaneously in Patients With Early HER2-positive Breast Cancer

NCT02286362 is registered in ClinicalTrials.gov with Hoffmann-La Roche as lead sponsor.

NCT NCT02286362
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02286362 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Observational Study of the Safety of Herceptin Given Subcutaneously in Patients With Early HER2-positive Breast Cancer
Lead sponsor
Hoffmann-La Roche
Phase
Observational
Overall status
Completed
Start date
January 14, 2015
Completion date
November 10, 2016
Enrollment
510 (actual)
Sites
97

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer